Detail Information of Xenobiotics

General Information of Xenobiotics (ID: XEO00301)
Xenobiotics Name
Irinotecan hydrochloride
Xenobiotics Type
Pharmaceutical Agent(s)
Classification
Approved/Marketed Drug
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=74990"></iframe>
3D MOL 2D MOL
PubChem CID
74990
DME(s) Modulated by This Xenobiotics
DME(s) Inhibited by This Xenobiotics
Aldehyde dehydrogenase 1 (ALDH1) DME Info Homo sapiens [1]
Arylsulfatase B (ARSB) DME Info Homo sapiens [2]
Cytochrome P450 2A6 (CYP2A6) DME Info Homo sapiens [3]
Cytochrome P450 2C9 (CYP2C9) DME Info Homo sapiens [3]
Cytochrome P450 3A4 (CYP3A4) DME Info Homo sapiens [4]
Dihydrothymine dehydrogenase (DPYD) DME Info Homo sapiens [1]
Myeloperoxidase (MPO) DME Info Homo sapiens [1]
Quinone reductase 1 (NQO1) DME Info Homo sapiens [2]
DME(s) Induced by This Xenobiotics
Carboxylesterase 2 (CES2) DME Info Homo sapiens [5]
Putrescine acetyltransferase (SSAT1) DME Info Homo sapiens [6]
Thiopurine methyltransferase (TPMT) DME Info Homo sapiens [2]
Xenobiotics-DME Activity Data
Xenobiotics-DME Activity Data Cytochrome P450 3A4 (CYP3A4) DME Info Ki = 24 microM [4]
References
1 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
2 Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
3 Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos. 2002 Apr;30(4):391-6.
4 Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54.
5 Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther. 2006 Nov;5(11):1450-6.
6 5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Res. 2004 Mar-Apr;24(2A):417-23.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.